J. E. Wraith

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer, J. E. Wraith, Michael Beck et al. · Genetics in Medicine · 2006 · 585 citations · Full text

Life Sciences, Biochemistry, Enzymology +10

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006 · 364 citations

Life Sciences, Biochemistry, Pharmacotherapy +7

Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I

L. Clarke, J. E. Wraith, Michael Beck et al. · PEDIATRICS · 2008 · 346 citations

Pharmacy, Pharmacotherapy, Biopharmaceutics +12

Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome

Paul Gissen, Colin A. Johnson, Neil V. Morgan et al. · Nature Genetics · 2004 · 339 citations

Life Sciences, Molecular Biology, Molecular Genetics +11

Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-<scp>l</scp>-Iduronidase (Laronidase)

J. E. Wraith, Michael Beck, Roderick Lane et al. · PEDIATRICS · 2007 · 246 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +9